One of the most controversial aspects of Neuroendocrine Tumours (NETs) is the ‘benign vs malignant’ question. It’s been widely debated, and it frequently patrols the various patient forums and other social media platforms. It raises emotions and it triggers many responses ….. at least from those willing to engage in the conversation. At best, this issue can cause confusion, at worst, it might contradict what new patients have been told by their physicians (….or not been told). This post will not cover Neuroendocrine Carcinoma which by standard cancer nomenclature definition is malignant.
Any standard cancer nomenclature definition of the word ‘tumour’ will confirm the definition of the word tumour means it can either be benign or malignant. The other connotation of ‘benign’ is that some might say it is not a cancer. But let’s be clear, Neuroendocrine Tumours are cancer.


However, and while I’m sure there are some NETs which might be academically described as ‘benign’, the key statement to explain any slow-growing or indolent NET is that they all have malignant potential – thus why surveillance and follow-up are really important. This was the key factor in the changes found in the 2010 Digestive System World Health Organisation (WHO) classification system from the previous ‘flaky’ version. This reinforcement of the malignant potential of all NETs was duplicated in the recent 2017 Endocrine System and 2019 Digestive System equivalents, which is now proposed as a classification scheme for all NETs (see below).
“Carcinoid”
Of course, we are not helped by the continued use of the term Carcinoid which decodes to ‘Carcinoma Like’ – that is potentially regressing the work of those specialists who are trying to undo over 100 years of complacency in the medical world (….. and it’s not really the type of awareness we need). The word is gradually being erased from NET nomenclature and the recent 2018 proposal by the International Agency for Research on Cancer (IARC) and WHO NET expert consensus panel to ditch it from the remaining versions of out of date WHO classifications (e.g. Pulmonary/Lung, Pituitary, Head & Neck, Genito-urinary, Adrenal and Paraganglia, Skin), may be the final nail in the coffin for Carcinoid. RIP Carcinoid. This also supports our awareness issues with the media reporting the wrong cancer types based on anatomy of the primary tumour.
Dear Doctors, Patient Advocates, Patients ….. Please stop using the word, it’s not helpful!
I’ve lost count of the stories from Neuroendocrine Cancer patients who have been told their tumour was benign but then returned to specialists at a later stage with incurable and metastatic cancer. There are doctors who clearly do not understand NETs and/or are not aware of the changes in WHO classification schemes from 2010 onwards. Sure, some will prove to be ‘benign’ in nature and may not cause many issues but any Ki-67 below 3% is a formal cancer grade of a Neuroendocrine Neoplasm. I accept that it’s currently difficult to work out which cases will turn more aggressive and when, thus why surveillance and follow-up are really important and also why patients should be seeing doctors who understand NETs. More sensitive molecular markers assisting doctors in decision-making will be welcome at some point in the future. Worth also noting that many slow-growing and indolent tumours can still often produce troublesome NET syndromes.
I’ve even heard one patient story where it was claimed a doctor called a metastatic NET case benign! Any standard cancer nomenclature definition of ‘benign’ on any respectable cancer site will include the statement that they do not spread to other parts of the body. The NET patient world is full of slow-growing Grade 1 Stage 4 patients. By dint of the stage number, they’re all malignant.
Read more detail in the articles below as these issues are inextricably linked.
I’m sure there are scenarios in all cancers where tumours can be benign and will never harm the person but if a doctor says you have a Neuroendocrine Tumour and not to worry because it’s benign, ask questions. Start with “how do you know it will never turn malignant” and “what will be done going forward to check”. This is particularly important in cases of Small Intestine and Pancreatic NETs where there is a greater risk of spread than other NET types.
I also acknowledge that many slow-growing localised NETs have much less prevalence for spread, i.e. Appendiceal NET, Rectal NET, and to a certain extent atypical Lung NET. Epidemiological data confirm these have less risk of spreading and there are curative scenarios in completed removing the localised primary with the right margins.




Thanks for listening
Click here and answer all questions to join my private Facebook group
Thanks for reading.
Ronny
Disclaimer
Check out my WEGO Health Awards
Check out my Glossary of Terms – click here
Please Share this post for Neuroendocrine Cancer awareness and to help another patient
- SYHX2008: A New Self‑Injectable subcutaneous Long‑acting Octreotide on the Horizon for NETs
Disclaimer:Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the… Read more: SYHX2008: A New Self‑Injectable subcutaneous Long‑acting Octreotide on the Horizon for NETs - Small tumours – big impact
In oncology, a “small” tumour generally refers to a mass that is 2cm or less in diameter. Tumours under 1 cm are often described as “very small”. These small growths typically fall into the earliest clinical staging categories (such as T1) where they are highly localized and have not spread beyond nearby structures. Tumor Size… Read more: Small tumours – big impact - The Invisibility of Neuroendocrine Tumours (NET) – an awareness post by Ronny Allan
“Invisible cancer” typically refers to malignancies that evade early detection or disguise themselves as other common, non-life-threatening ailments. This term is very frequently associated with Neuroendocrine Tumours which are very often difficult to spot on standard imaging and blood tests. When I was diagnosed, I didn’t even feel ill. It was therefore a bit of… Read more: The Invisibility of Neuroendocrine Tumours (NET) – an awareness post by Ronny Allan - Clinical Study from the Australasian Gastro-Intestinal Trials Group (AGITG) STOPNET
Disclaimer:Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the… Read more: Clinical Study from the Australasian Gastro-Intestinal Trials Group (AGITG) STOPNET - Spotlight on Ovarian Neuroendocrine Neoplasms
Disclaimer: The information in this Spotlight is provided for general information and education only. It is not intended to replace the advice of a qualified healthcare professional, nor to be used for diagnosis or treatment of any medical condition. Always discuss your individual situation, symptoms, test results, and treatment options with your own doctor… Read more: Spotlight on Ovarian Neuroendocrine Neoplasms - Ronny Allan’s Newsletter covering May 2026
Just back from holiday thus why the late publication! Summary of May 2026 on RonnyAllan.NET I think the main story of May is similar to March and April which was a strong blog performance. Other key targets met were the two main primary NET types (small intestine and pancreas) and one not so common(thymus) have finally been… Read more: Ronny Allan’s Newsletter covering May 2026 - Fat‑Soluble Vitamins in Neuroendocrine Tumours (NETs): Why Deficiency Happens and Who Is Most at Risk
This blog provides general educational information only. It does not offer medical advice, diagnosis, or treatment. Patients should always consult their clinical team for personalised guidance. Introduction: What Are Fat‑Soluble Vitamins? Fat‑soluble vitamins — A, D, E and K — are nutrients that can only be absorbed when dietary fat is digested properly. They… Read more: Fat‑Soluble Vitamins in Neuroendocrine Tumours (NETs): Why Deficiency Happens and Who Is Most at Risk - Neuroendocrine Tumours (NETs) – A Spotlight on Vitamin B9 (Folate)
Before you read thisThis information is designed to help you understand how vitamins work in the body and how certain NET-related factors might affect them. It is not a substitute for personalised medical advice. Every NET patient is different — tumour type, treatments, surgery, symptoms, and nutritional needs can vary widely. If you have concerns… Read more: Neuroendocrine Tumours (NETs) – A Spotlight on Vitamin B9 (Folate) - Neuroendocrine Tumours – A Spotlight on Vitamin E (Tocopherols & Tocotrienols)
🟧A general‑population overview with NET‑specific considerations where relevant. Disclaimer: This Spotlight provides general educational information about Vitamin E. It is not a substitute for medical advice. Individual needs vary, particularly for those with conditions affecting digestion or absorption. Always consult your medical team before making changes to supplements or nutrition. What is Vitamin E? Vitamin… Read more: Neuroendocrine Tumours – A Spotlight on Vitamin E (Tocopherols & Tocotrienols) - Neuroendocrine Tumours – A Spotlight on Vitamin A (Retinol)
Disclaimer: This Spotlight provides general educational information about Vitamin A. It is not a substitute for medical advice. Individual needs vary, particularly for those with conditions affecting digestion, absorption, or liver function. Always consult your medical team before making changes to supplements or nutrition. 🟧A general‑population overview with NET‑specific considerations where relevant. What is Vitamin… Read more: Neuroendocrine Tumours – A Spotlight on Vitamin A (Retinol) - 200 Lanreotide Injections: A Milestone in Long‑Term Neuroendocrine Tumour (NET) Management
Disclaimer: Educational and advocacy content only. Not a substitute for medical advice. Two hundred injections. It’s a milestone that carries weight — not because of the number itself, but because of what it represents: continuity, stability, and the lived reality of managing Neuroendocrine Cancer over the long term. Lanreotide has been part of my life… Read more: 200 Lanreotide Injections: A Milestone in Long‑Term Neuroendocrine Tumour (NET) Management - Neuroendocrine Tumours (NETs) – A Spotlight on Vitamin K (Phylloquinone / Menaquinones)
Before you read thisThis information is designed to help you understand how vitamins work in the body and how certain NET-related factors might affect them. It is not a substitute for personalised medical advice. Every NET patient is different — tumour type, treatments, surgery, symptoms, and nutritional needs can vary widely. If you have concerns… Read more: Neuroendocrine Tumours (NETs) – A Spotlight on Vitamin K (Phylloquinone / Menaquinones) - A spotlight on Colon Neuroendocrine Neoplasms
Disclaimer: This Spotlight is for general information only and should not be used as a substitute for personalised medical advice. Neuroendocrine neoplasms (NENs) are diverse, and individual cases vary. Always discuss your specific situation, test results, and treatment options with your own specialist team. Content reflects current evidence and classifications at the time of writing… Read more: A spotlight on Colon Neuroendocrine Neoplasms - Spotlight on Thymic Neuroendocrine Neoplasms (Thymic NENs)
Disclaimer:The information in this Spotlight is for general education and awareness. It does not replace personalised medical advice, diagnosis, or treatment. Thymic Neuroendocrine Neoplasms (NENs) are complex and highly variable, and individual cases may differ significantly from the patterns described here. Always discuss your own situation, test results, and treatment options with your specialist team,… Read more: Spotlight on Thymic Neuroendocrine Neoplasms (Thymic NENs)
Discover more from Ronny Allan - Living with Neuroendocrine Cancer
Subscribe to get the latest posts sent to your email.



I was incensed when a locum that I was seeing at our local hospital about an unrelated issue questioned whether or not I actually had cancer! Yes, my NETS is cancer! Why in the world would I claim to have cancer if I didn’t?
I feel this is the MOST important issue that I’ve encountered, my father encountered and has left some young people in the serious position of “inoperable” when their “mets” were discovered after an initial diagnosis of benign. I myself could have easily fallen into this crack in the sidewalk when my local GP and surgeon said first tumor was “benign” . . . But my father’s “benign” tumor came back and killed him when he had mets to his bones. FOLLOW-UP IS EXTREMELY IMPORTANT . . . The reason I’m alive 11 years after first SDHB Deficient tumor diagnosis.